Jeffrey W. Albers - Net Worth and Insider Trading
Jeffrey W. Albers Net Worth
The estimated net worth of Jeffrey W. Albers is at least $16 Million dollars as of 2024-11-28. Jeffrey W. Albers is the Director of Blueprint Medicines Corp and owns about 157,557 shares of Blueprint Medicines Corp (BPMC) stock worth over $15 Million. Jeffrey W. Albers is the Director of Spyre Therapeutics Inc and owns about 27,360 shares of Spyre Therapeutics Inc (SYRE) stock worth over $759,240. Jeffrey W. Albers is also the Director of Kymera Therapeutics Inc and owns about 0 shares of Kymera Therapeutics Inc (KYMR) stock worth over $0. Details can be seen in Jeffrey W. Albers's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jeffrey W. Albers has not made any transactions after 2024-11-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jeffrey W. Albers
Jeffrey W. Albers Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jeffrey W. Albers owns 3 companies in total, including Blueprint Medicines Corp (BPMC) , Kymera Therapeutics Inc (KYMR) , and Magenta Therapeutics Inc (MGTA) .
Click here to see the complete history of Jeffrey W. Albers’s form 4 insider trades.
Insider Ownership Summary of Jeffrey W. Albers
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2024-11-07 | director & CEO & President |
| KYMR | Kymera Therapeutics Inc | 2024-08-26 | director |
| MGTA | Magenta Therapeutics Inc | 2018-06-20 | director |
Jeffrey W. Albers Latest Holdings Summary
Jeffrey W. Albers currently owns a total of 3 stocks. Among these stocks, Jeffrey W. Albers owns 157,557 shares of Blueprint Medicines Corp (BPMC) as of November 7, 2024, with a value of $15 Million and a weighting of 95.18%. Jeffrey W. Albers owns 27,360 shares of Spyre Therapeutics Inc (SYRE) as of November 6, 2024, with a value of $759,240 and a weighting of 4.82%. Jeffrey W. Albers also owns 0 shares of Kymera Therapeutics Inc (KYMR) as of August 26, 2024, with a value of $0 and a weighting of 0%.
Latest Holdings of Jeffrey W. Albers
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2024-11-07 | 157,557 | 95.10 | 14,983,671 |
| SYRE | Spyre Therapeutics Inc | 2024-11-06 | 27,360 | 27.75 | 759,240 |
| KYMR | Kymera Therapeutics Inc | 2024-08-26 | 0 | 46.86 | 0 |
Holding Weightings of Jeffrey W. Albers
Jeffrey W. Albers Form 4 Trading Tracker
According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 29 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years, including 0 buys and 29 sells. The most-recent trade in Blueprint Medicines Corp is the sale of 5,000 shares on November 7, 2024, which brought Jeffrey W. Albers around $510,000.
According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 2 transactions in Spyre Therapeutics Inc (SYRE) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Spyre Therapeutics Inc is the sale of 6,700 shares on November 6, 2024, which brought Jeffrey W. Albers around $246,292.
According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 3 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Kymera Therapeutics Inc is the sale of 5,000 shares on August 26, 2024, which brought Jeffrey W. Albers around $245,500.
Insider Trading History of Jeffrey W. Albers
- 1
Jeffrey W. Albers Trading Performance
Jeffrey W. Albers Ownership Network
Jeffrey W. Albers Owned Company Details
What does Blueprint Medicines Corp do?
Who are the key executives at Blueprint Medicines Corp?
Jeffrey W. Albers is the director & CEO & President of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include President & R and D Fouad Namouni , Principal FAO Michael Landsittel , and Chief Commercial Officer Philina Lee .
Blueprint Medicines Corp (BPMC) Insider Trades Summary
Over the past 18 months, Jeffrey W. Albers made 11 insider transaction in Blueprint Medicines Corp (BPMC) with a net sale of 170,808. Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 38,146 shares made by Michael Landsittel , a net sale of 14,415 shares made by Ariel Hurley , and a net sale of 9,342 shares made by Christopher K. Murray .
In summary, during the past 3 months, insiders sold 48,159 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 48,159 shares. During the past 18 months, 489,690 shares of Blueprint Medicines Corp (BPMC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 489,690 shares.
Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Blueprint Medicines Corp Insider Transactions
Jeffrey W. Albers Mailing Address
Above is the net worth, insider trading, and ownership report for Jeffrey W. Albers. You might contact Jeffrey W. Albers via mailing address: Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
